Dr. Prasad Adusumilli –the leading scientist and Thoracic surgeon at MSK (Memorial Sloan Kettering) Cancer Center believes that personalized gene therapy can soon help in changing the manner pleural mesothelioma is being treated in the current scenario.
Currently, Dr. Prasad is serving as the principal investigator of a phase I clinical trial that involves the participation of customized immune cells –referred to as CAR (Chimeric Antigen Receptor) T-cells, showing relevant improvement in the overall treatment of mesothelioma. As per Dr. Prasad, the revolutionary CAR T-cells might change the overall method of treating mesothelioma in the coming times.
CAR T-Cells Working Over Solid Tumors
Dr. Prasad singled out a patient of 73 years having mesothelioma with the help of the CAR T-cell therapy along with the combination of Keytruda. This combination helped in improving the overall efficiency and extending the duration of the given type of treatment. The patient obtained the complete suite of metabolic response to the given treatment. Moreover, the patient is doing well in the current scenario after 16 months –without any further treatment.
As a major part of the clinical trials including breast cancer as well as lung cancer patients, five other patients having mesothelioma received the given combination. Out of them, two reflected partial response, two responded having progressive disease, and one responded with stable disease.
All of the patients are still alive since the treatment and have not shown any signs of side effects. Gene therapy in the treatment of mesothelioma consists of the laboratory reprogramming of the self T cells of the patient’s body. It helps in the removal of cells with the help of a specific protein that has been aimed at a particular target before it returns the same to the patient.
The Effectiveness of CAR T-Cell Therapy
The revolutionary CAR T-cell therapy functions by aiding the own immune system of the patient towards better recognizing & destroying the cancer cells. The United States FDA (Food and Drug Administration) had given approval to the first gene therapy for treating pediatric leukemia in the year 2017. This provides for the official commencement of a new, revolutionary treatment approach to the treatment of cancer.
Dr. Prasad states that this might be the future of cancer treatment. As a group at MSK, the team of researchers is conducting a more in-depth study to observe the true results of the treatment.